Introdução O transtorno de ansiedade social (TAS) é um transtorno muito prevalente e incapacitante em crianças e adolescentes. Esse estudo foi delineado para avaliar a eficácia e a tolerabilidade de um inibidor seletivo da recaptação de serotonina altamente potente, o escitalopram, no tratamento do TAS em crianças e adolescentes. Métodos Vinte pacientes ambulatoriais com um diagnóstico principal de TAS foram tratados com escitalopram em um ensaio clínico aberto por 12 semanas. A medida de desfecho primária foi a mudança basal em comparação à final na Clinical Global Impression – Improvement Scale (CGI-I). As medidas de desfecho secundárias foram a CGI – Severity scale (CGI-S), a Social Phobia and Anxiety Inventory for Children (SPAI-C), a Screen for Child and Anxiety Related Emotional Disorders (SCARED) – Child and Parent version, e a The Youth Quality of Life Instument- Research Version (Y-QOL-R). Resultados Na escala CGI-I, 13 dos 20 pacientes (65%) tiveram um escore ≤ 2, correspondendo a uma resposta ao tratamento. Todas as medidas sintomáticas e de qualidade de vida mostraram melhoras significativas da avaliação basal à semana 12, com grandes tamanhos de efeito, variando de 0.9 a 1.9 (todos p < 0.01). O escitalopram foi geralmente bem tolerado. Conclusões Esses resultados sugerem que o escitalopram pode ser um tratamento eficaz e seguro no tratamento do TAS pediátrico. Futuros ensaios clínicos randomizados, placebo-controlados, fazem-se necessários. / Introduction Social anxiety disorder (SAD) is a highly prevalent and disabling disorder in children and adolescents. This study was designed to evaluate the efficacy and safety of a highly potent and selective serotonergic reuptake inhibitor, escitalopram, in the treatment of SAD in children and adolescents. Methods Twenty outpatients with a primary diagnosis of SAD were treated in a 12-week open trial with escitalopram. The primary outcome variable was the change from baseline to endpoint in Clinical Global Impression – Improvement scale (CGI-I). Secondary efficacy measures included the CGI – Severity scale (CGI-S), the Social Phobia and Anxiety Inventory for Children (SPAI-C), the Screen for Child and Anxiety Related Emotional Disorders (SCARED) – Child and Parent version, and The Youth Quality of Life Instument-Research Version (Y-QOL-R). Results On the CGI-I scale, 13 of 20 patients (65%) had a score ≤ 2, meaning response to treatment. All symptomatic and quality of life measures showed improvements from baseline to week-12, with large effect sizes ranging from 0.9 to 1.9 (all p < 0.01). Escitalopram was generally well-tolerated. Conclusion These results suggest that escitalopram may be an effective and safe treatment for pediatric SAD. Future placebo-controlled randomized clinical trials are warranted.
| Identifer | oai:union.ndltd.org:IBICT/oai:lume.ufrgs.br:10183/10730 |
| Date | January 2007 |
| Creators | Isolan, Luciano Rassier |
| Contributors | Manfro, Gisele Gus, Rohde, Luis Augusto Paim |
| Source Sets | IBICT Brazilian ETDs |
| Language | Portuguese |
| Detected Language | English |
| Type | info:eu-repo/semantics/publishedVersion, info:eu-repo/semantics/masterThesis |
| Format | application/pdf |
| Source | reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, instname:Universidade Federal do Rio Grande do Sul, instacron:UFRGS |
| Rights | info:eu-repo/semantics/openAccess |
Page generated in 0.0029 seconds